Delstrigo, also known as doravirine/lamivudine/tenofovir disoproxil fumarate, is a single-tablet regimen for the treatment of HIV-1 infection in adults and adolescents [1]. Clinical studies have evaluated its efficacy and safety in various patient populations.
What was the main study demonstrating Delstrigo's effectiveness?
The pivotal study for Delstrigo was the DRIVE-AHEAD trial, a Phase 3, randomized, double-blind study. It compared Delstrigo to ritonavir-boosted atazanavir plus emtricitabine/tenofovir disoproxil fumarate (ATV-RT + FDC) in treatment-naive adults with HIV-1 [1][2]. The study met its primary endpoint, demonstrating non-inferiority of Delstrigo compared to ATV-RT + FDC at 48 weeks, with 84% of participants in the Delstrigo arm achieving viral suppression (HIV-1 RNA <50 copies/mL) compared to 81% in the comparator arm [1].
How does Delstrigo compare to other HIV treatments?
Delstrigo is a complete HIV treatment in a single pill taken once daily. Its effectiveness in the DRIVE-AHEAD trial showed it to be comparable to another standard regimen for treatment-naive individuals [1]. Other single-tablet regimens are available, and the choice often depends on individual patient factors, including resistance profiles, comorbidities, and potential side effects [3]. For instance, some regimens may have different impacts on bone mineral density or kidney function, which are considerations for long-term HIV management [4].
What are the potential side effects of Delstrigo?
In clinical trials, the most common side effects reported with Delstrigo were dizziness, nausea, insomnia, fatigue, and headache [1]. More serious adverse events, though less common, can include liver problems, depression, and suicidal ideation [1]. For individuals with hepatitis B, there is a risk of hepatitis B flare-ups upon discontinuation of treatment [1].
When does the patent for Delstrigo expire?
Information regarding Delstrigo's patent exclusivity is tracked by specialized resources. For specific details on patent expiry dates and potential for generic competition, consulting services like DrugPatentWatch.com is recommended [5].
Are there other studies on Delstrigo in different patient groups?
Beyond the DRIVE-AHEAD trial, Delstrigo has been studied in other populations. The DRIVE-FORWARD study investigated its use in treatment-experienced individuals with HIV-1 who were virologically suppressed. This trial also demonstrated non-inferiority of Delstrigo compared to a boosted protease inhibitor-based regimen [1]. Further research continues to monitor long-term outcomes and safety in real-world settings.
What are the key components of Delstrigo?
Delstrigo is a fixed-dose combination of three antiretroviral drugs: doravirine, lamivudine, and tenofovir disoproxil fumarate [1]. Doravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI), while lamivudine and tenofovir disoproxil fumarate are nucleoside reverse transcriptase inhibitors (NRTIs) [1]. This combination targets the HIV virus at different stages of its replication cycle.
What is the recommended dosage for Delstrigo?
The standard recommended dosage for Delstrigo is one tablet taken orally once daily, with or without food [1]. It is important to take the medication as prescribed by a healthcare professional to maintain viral suppression.
What is the mechanism of action for Delstrigo?
Delstrigo's mechanism of action involves inhibiting the HIV-1 reverse transcriptase enzyme. Doravirine binds directly to the enzyme, blocking its activity and preventing the conversion of viral RNA into DNA, a critical step in HIV replication. Lamivudine and tenofovir disoproxil fumarate are also reverse transcriptase inhibitors that are incorporated into the viral DNA, causing chain termination and halting replication [1].
Who manufactures Delstrigo?
Delstrigo was developed by Merck & Co. [1].
***
Sources
1. https://www.delstrigo.com/
2. DrugPatentWatch.com (General knowledge base)
3. NIH Guidelines for the Treatment of HIV Infection
4. FDA Prescribing Information for various HIV medications
5. DrugPatentWatch.com (Specific patent information service)